Charming Medical Limited Class A Ordinary Shares (MCTA) Revenue History
Annual and quarterly revenue from 2022 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MCTA Revenue Growth
MCTA Revenue Analysis (2022–2024)
As of May 8, 2026, Charming Medical Limited Class A Ordinary Shares (MCTA) generated trailing twelve-month (TTM) revenue of $0.
Looking at the longer-term picture, MCTA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $6.2 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including CANG (+1197.2% YoY), CLOV (+48.7% YoY), and ACMR (+15.2% YoY). Compare MCTA vs CANG →
MCTA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MCTACurrent | $0 | - | - | 22.3% | |
 CANG | $804M | +1197.2% | -11.0% | 22.2% | |
 CLOV | $1.9B | +48.7% | +23.4% | -4.4% | |
 ACMR | $901M | +15.2% | +41.9% | 12.1% | |
 BTBT | $164M | - | - | 16.8% | |
 AEYE | $40M | +14.5% | +14.5% | -7.9% |
MCTA Historical Revenue Data (2022–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $6.2M | +3.4% | $4.2M | 67.2% | $1.4M | 22.3% |
| 2023 | $6.0M | +70.4% | $3.9M | 65.1% | $1.0M | 16.8% |
| 2022 | $3.5M | - | $1.5M | 42.3% | $-521,336 | -14.8% |
See MCTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MCTA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMCTA — Frequently Asked Questions
Quick answers to the most common questions about buying MCTA stock.
Is MCTA's revenue growth accelerating or slowing?
MCTA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MCTA's long-term revenue growth rate?
Charming Medical Limited Class A Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MCTA's revenue distributed by segment?
MCTA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2022-2024 are available for download. Segment mix reveals concentration and diversification trends.